5 more COVID-19 vaccine manufacturers have yet to get EUA in the Philippines, according to the FDA.
The Food and Drug Administration (FDA) on Monday said that 5 more COVID-19 vaccine manufacturers have yet to get emergency use authorization (EUA) in the Philippines.
In a briefing with President Rodrigo Duterte, FDA Director-General Eric Domingo said those still processing their applications were Bharat Biotech, Johnson & Johnson, and Sinopharm.
Bharat Biotech applied for an emergency use authorization last January 22, but they’re still lacking proof of good manufacturing practice. On the other hand, Johnson & Johnson’s Janssen applied for an emergency use authorization last March 31.
Domingo also said that someone told them that Sinopharm was interested in applying for an emergency use authorization for its COVID-19 vaccine, but it had yet to submit requirements.
“Ang hindi pa malinaw po sa atin ay Sinopharm. May sumulat po sa amin na gustong mag-apply pero noong hiningian po namin ng requirements, hindi pa po nila ibinibigay,” Domingo said.
Moreover, Domingo said that Novovax and Moderna have yet to apply for an emergency use authorization.
Domingo also said that the single-dose COVID-19 vaccine developed by Johnson & Johnson (J&J) was expected to be granted with an EUA by the Philippine Food and Drug Administration (FDA) this week.
Once authorized, Johnson & Johnson will be the fifth COVID-19 vaccine manufacturer in the Philippines to get regulatory approval, following Pfizer-BioNTech, Oxford-AstraZeneca, Sinovac Biotech, and Gamaleya.
What can you say about this? Let us know your thoughts in the comments below.